What is Arecor?
Arecor is a biopharmaceutical firm dedicated to enhancing therapeutic medicines through its proprietary Arestat technology platform. The company focuses on developing innovative treatments for diabetes and other cardiometabolic diseases, collaborating with leading pharmaceutical and medtech entities. Its robust intellectual property portfolio validates the efficacy and potential of its technology, positioning it as a key player in the development of advanced drug delivery systems.
How much funding has Arecor raised?
Arecor has raised a total of $8M across 2 funding rounds:
Private Equity
$230K
Unspecified
$7.8M
Private Equity (2015): $230K with participation from Hygea VCT Plc
Unspecified (2018): $7.8M led by Albion Capital Group, Downing, and Calculus Capital
Key Investors in Arecor
Albion Capital Group
AlbionVC, the technology investment arm of Albion Capital Group LLP, focuses on high-growth B2B software and technology-enabled services companies, primarily investing from seed to Series B in the UK.
Downing
Downing is a London-based financial services company that designs and manages investment products.
Calculus Capital
Calculus Capital is an investment manager specializing in tax-efficient growth capital for UK smaller companies, investing in technology, healthcare, and creative industries.
What's next for Arecor?
The recent major strategic investment signals a pivotal growth phase for Arecor, likely enabling the company to accelerate its clinical development pipeline and expand its market reach. This capital infusion is expected to support the advancement of its Arestat technology platform and further solidify its collaborations within the pharmaceutical and medtech sectors. The company's focus on diabetes and cardiometabolic diseases, coupled with its strong IP, suggests a strategic direction towards addressing significant unmet medical needs.
See full Arecor company page
